The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
A bit of perspective. Genmab have likely just spent less than 1% of their net cash on the Scancell mab. I don’t think we are gonna be featuring much in the chats, though I’d like to be proven wrong..
As mentioned by bermuda and others, calculus appear to be selling. I imagine in the current environment they will be wary that many of their less well funded company investments may come calling for cash faster and in higher quantity than originally hoped ie calculus need liquidity. This would explain the muted reaction to an RNS which, as others have attested, is about as good as could be hoped at this stage. I’ve added.
It’s an interesting point crumbs and I’m pleased with the RNS today. My guess is max $3m upfront. I’ve seen those big future milestone numbers too many times to take it too seriously. As another poster suggested however, it may encourage others to follow. ATB
I’m pretty sure if sclp got $54m upfront then it would be in the RNS. Why wouldn’t they show it? Our tech is amazing with big upfront value etc..The world is awash with big sounding deals with limited upfront, that ultimately dissolve to nothing, as I’m sure the likes of bermuda will attest. I own over 1m shares, but would like to know the upfront before claiming this is cracking news. Good news yes, but not cracking.
??? Well of course the fund/assets will be used to pay the pensioners each year. What else do you think it is there for? The assets will fall each year due to the pension payout, and the corresponding liability will also fall.
I think 68p was hit because Carclo came to be seen as a covid play, with punters buying into the dream that abundant tests and injectables would be needed. When that froth dissipated, so did the short term punters. But any investor who believes now the current fundamentals justify a 68p+ valuation - and that the obstacle is simply lack of communication - should be buying the stock in droves IMO. If that sort of premium can be justified then very often the market will find a way of realising it, even if current management cannot. My own belief is that this management team will get there, and I’m happy trusting my investment with them.
With respect cherryhiller, I couldn’t disagree more. I think the new management team have done a great job growing the business out of the ashes of the wipac problems, solidifying the financial position with both the banks and trustees, and communicating the story to shareholders. The 68p price you refer to is rather selective. Carclo was also trading at 4p in recent years when the market gave it little chance of surviving. Not only has it strongly recovered from those levels but I suspect the future for holders will be a glowing one, in large part thanks to management action. ATB
Seems the MM’s are maintaining an entirely false market in these shares. At the reported bid and ask, you can buy large quantities of stock, but cannot sell even the smallest amount. This really shouldn’t be allowed to go on. Who is supplying the market with shares? Is it a person with managerial and thus inside status? If so, why are the sells not reported? Leaves a very poor taste.
Yes. Shocking that a stock with a full LSE listing is allowed to move in this way. No visibility to understand such violent swings, little reported volume, no word from management, no purchases from management… really shoddy :(
Chief Executive Officer, Neil Martin, was paid £628k by RM last year, yet he has not made a single share purchase in the business since the stock plummeted last month. Given the absolute farce going on, the least he could do is put some of that money where his mouth is. IMO
Unfortunately, the FDA and not Avion decide which drugs get approved, and they haven’t seen enough evidence yet. 5+ upticks suggests a lot of hot air already built into price, one wonders whether trial approval will be a damp squib :(